Platelet function during ticlopidine and eicosapentaenoic Acid administration in patients with coronary heart disease.
Antiplatelet drugs have been reported to be useful in unstable angina. This study was designed to investigate the effects of simultaneous administration of ticlopidine and eicosapentaenoic acid (EPA) on platelet function in coronary heart disease (CHD) patients. Ticlopidine significantly reduced platelet aggregation induced by ADP and collagen with no effect on arachidonate metabolism. The aggregation responses to collagen, ADP and arachidonate were not altered significantly by EPA (as fish oil) intake whereas thromboxane A(2) formation was reduced, but not completely inhibited. Combined therapy seems to achieve a more marked degree of inhibition of aggregation together with a fall in the urinary excretion of 11-dehydrothromboxane B(2) metabolite. Therefore, in CHD patients ticlopidine therapy plus fish oil administration could be useful to inhibit two different mechanisms (TxA(2)- and ADP-dependent) of platelet activation.